ArticleJournal of bone oncology2016
The role of osteoclasts in breast cancer bone metastasis.
Article in Journal of bone oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of bone marrow adipocytes in bone metastasis development and progression: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Decoding triple negative breast cancer bone metastasis: from 3D bioprinted models to clinical translation.Journal of nanobiotechnology · 2026Review
- Koumine inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss via suppression of the MAPK signaling pathways.Scientific reports · 2026Article
- In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors.Current issues in molecular biology · 2025Article
- Cannabinoid Receptor Type 2 Agonist, GW405833, Reduced the Impacts of MDA-MB-231 Breast Cancer Cells on Bone Cells.Cancer medicine · 2025Article
- The role of exosomal non-coding RNAs in the breast cancer tumor microenvironment.Functional & integrative genomics · 2025Review
- Therapeutic potential of Triptolide in inhibiting breast cancer-induced bone destruction - PTHrP as a therapeutic target.Frontiers in pharmacology · 2025Article
- Harnessing curcumin and nanotechnology for enhanced treatment of breast cancer bone metastasis.Discover nano · 2024Review
- Pre-metastatic niche: formation, characteristics and therapeutic implication.Signal transduction and targeted therapy · 2024Review
- [miRNA Is Involved in the Pathogenesis of Multiple Diseases by Targeting Osteoprotegerin].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Calcium-based biomaterials: Unveiling features and expanding applications in osteosarcoma treatment.Bioactive materials · 2024Review
- Protein cargo in extracellular vesicles as the key mediator in the progression of cancer.Cell communication and signaling : CCS · 2024Review
- Altered gut microbiome drives heightened pain sensitivity in a murine model of metastatic triple-negative breast cancer.American journal of cancer research · 2024Article
- Osteoclast-derived apoptotic bodies inhibit naive CD8Cell reports. Medicine · 2023Article
- The Secretome of Parental and Bone Metastatic Breast Cancer Elicits Distinct Effects in Human Osteoclast Activity after Activation of β2 Adrenergic Signaling.Biomolecules · 2023Article
- High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.Scientific reports · 2023Article
- Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy.JBMR plus · 2023Article
- Review
- Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment.Materials (Basel, Switzerland) · 2022Review
- miR-92a-3p encapsulated in bone metastatic mammary tumor cell-derived extracellular vesicles modulates mature osteoclast longevity.Cancer science · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer frequently metastasises to the skeleton, interfering with the normal bone remodelling process and inducing bone degradation. Bone degradation is caused by osteoclasts, the normal bone-resorbing cells. Osteoclast-mediated bone degradation subsequently leads to the release of bone-derived factors that promote skeletal tumour growth. Osteoclasts themselves stimulate tumour growth. This Review describes the molecular mechanisms through which osteoclasts and breast cancer cells collaborate with each other, triggering the formation of osteolytic bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.